Chemocentryx, Inc.

Amgen Inc.

Antoni Krasinski

Penglie Zhang

Yibin Zeng

Sreenivas Punna

Jay Patrick Powers

Rebecca M Lui

Jeffrey P McMahon

Junfa Fan

Solomon Ungashe

Pingchen Fan

Venkat Reddy Mali

Qiang Wang

Hiroko Tanaka

Christopher W Lange

Jaroslaw Kalisiak

Ju Yang

Xi Chen

Rajinder Paul Singh

Manmohan Reddy Leleti

Chao Yu

Trevor T Charvat

Wei Yu Chen

Dean R Dragoli

John Jessen Wright

Valentino J Stella

Andrew M K Pennell

Daniel J Dairaghi

Zheng Wei

Jimmie L Moore

Lianfa Li

Shichang Miao

Jeff Jin

Derek Hansen

Arindrajit Basak

Yang Song

James J Campbell

Karen Ebsworth

Timothy J Sullivan

Hiufung Chu

Cheng Hu

Aaron Robert Novack

Anita Melikian

Howard S Roth

Kwok Yau

Daniel R Marshall

Aubrie Harland

Jeffrey Mcmahon

Rajinder Singh

Aaron Novack

Jeffrey P Mcmahon

Compounds of formula (A) are provided which are useful in the treatment of diseases or conditions modulated at least in part by CCR6:

Aryl sulfonyl (hydroxy) piperidines as CCR6 inhibitors

Intermediates and methods are provided for the preparation of selected C5aR antagonist compounds.

Processes and intermediates in the preparation of C5aR antagonists

Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.

CXCR7 antagonists

Compounds are provided as chemokine inhibitors having the structure:

Modulators of chemokine receptors

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include dministering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C-X-C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula:

Methods of treating generalized pustular psoriasis with an antagonist of CCR6 or CXCR2

Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.

Heteroaryl sulfonamides and CCR2/CCR9

Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): 

Soluble C5aR antagonists

The present disclosure provides, inter alia, methods of treating generalized pustular psoriasis (GPP) by administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C&#x2014;X&#x2014;C motif chemokine receptor 2 (CXCR2) antagonist. Also provided herein are methods of modulating dysregulated IL-36 signaling in a subject in need thereof and methods of reducing neutrophil, inflammatory dendritic cell (iDC), and/or CD4 T cell accumulation in a subject in need thereof, said methods, include administering an effective amount of a Chemokine Receptor 6 (CCR6) antagonist and/or a C&#x2014;X&#x2014;C motif chemokine receptor 2 (CXCR2) antagonist. In some embodiments, the CCR6 and/or CXCR2 antagonist has the formula: 

Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1  Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.

Free base crystalline form of a complement component C5a receptor

Compounds are provided as chemokine inhibitors having the structure: 

Compounds are provided that act as potent antagonists of the CCR2 receptor. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases and as controls in assays for the identification of CCR2 antagonists. 

Fused heteroaryl pyridyl and phenyl benzenesuflonamides as CCR2 modulators for the treatment of inflammation

Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.

Aza-aryl 1H-pyrazol-1-yl benzene sulfonamides

Growing community of inventors

Sunnyvale, CA, United States of America

Antoni Krasinski